Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03229200 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03229200 · ClinicalTrials.gov record · last posted 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

StatusActive, Not Recruiting
PhasePhase 4
Started2017-05-22
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

Amendment record 39 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 39 times since 2017-07-24; most recent amendment 2025-10-28. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-10-28
Status change Enrolling by Invitation→Active, Not Recruitingv39
2018-09-06
Status change Recruiting→Enrolling by Invitationv9
Trial Details
NCT Number NCT03229200
Lead Sponsor Pharmacyclics Switzerland GmbH
Collaborators: Janssen Biotech, Inc., including Johnson & Johnson
Conditions Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Enrollment 297 participants
Start Date 2017-05-22
Primary Completion 2027-05-10 (estimated)
Study Completion 2027-05-10 (estimated)
Updated on ClinicalTrials.gov 2025-10-30